Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value per share, 5,000 shares authorized and no shares issued and outstanding as of June 30, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value per share, 250,000 shares authorized; 133,734 shares issued and outstanding as of June 30, 2026; 132,376 shares issued and outstanding as of December 31, 2025 | 1,337 | 1,324 |
| Additional paid-in capital | 7,716,958 | 7,510,473 |
| Accumulated other comprehensive loss | (32,138) | (20,097) |
| Accumulated deficit | (6,332,039) | (6,702,524) |
| Total stockholders' equity | 1,354,118 | 789,176 |
| Total liabilities and stockholders' equity | $5,558,769 | $4,966,331 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's AOCI?
- Alnylam Pharmaceuticals (ALNY) reported AOCI of -$32.14M in Q2 2026.
- How has Alnylam Pharmaceuticals's AOCI changed year-over-year?
- Alnylam Pharmaceuticals's AOCI decreased by 7.3% year-over-year, from -$29.95M to -$32.14M.
- What is the long-term trend for Alnylam Pharmaceuticals's AOCI?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's AOCI has grown at a -14.4% compound annual growth rate (CAGR), from -$43.62M to -$20.1M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Alnylam Pharmaceuticals's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude